Log In
Print
BCIQ
Print
Print this Print this
 

AGT-181

  Manage Alerts
Collapse Summary General Information
Company ArmaGen Technologies Inc.
DescriptionRe-engineered human iduronidase (IDUA), where the lysosomal enzyme is fused to IgG, a mAb
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Neurology (unspecified)
Indication DetailsTreat the brain in mucopolysaccharidosis I (MPS I, Hurler syndrome)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today